Sera Prognostics (NASDAQ:SERA) Announces Quarterly Earnings Results

Sera Prognostics (NASDAQ:SERA) announced its earnings results on Wednesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Zacks reports. During the same quarter in the prior year, the business posted ($0.25) EPS.

Sera Prognostics Stock Performance

SERA traded up $0.06 during trading on Wednesday, hitting $4.14. The stock had a trading volume of 57,117 shares, compared to its average volume of 142,782. The company has a market capitalization of $139.82 million, a PE ratio of -4.18 and a beta of 0.89. Sera Prognostics has a twelve month low of $3.84 and a twelve month high of $12.36. The stock has a 50 day simple moving average of $5.15 and a two-hundred day simple moving average of $6.62.

Insider Buying and Selling at Sera Prognostics

In other news, General Counsel Benjamin Jackson sold 7,912 shares of Sera Prognostics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $6.38, for a total transaction of $50,478.56. Following the completion of the sale, the general counsel now directly owns 120,561 shares in the company, valued at approximately $769,179.18. The trade was a 6.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Joshua Phillips sold 12,163 shares of Sera Prognostics stock in a transaction on Monday, January 13th. The stock was sold at an average price of $6.39, for a total transaction of $77,721.57. Following the sale, the director now owns 2 shares of the company’s stock, valued at $12.78. The trade was a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,877 shares of company stock worth $480,677 over the last three months. Corporate insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.